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Abstract: Fungi are a frequent cause of nosocomial infections, with an incidence that has 
increased significantly in recent years, especially among critically ill patients who require 
intensive care unit (ICU) admission. Among ICU patients, postsurgical patients have a higher 
risk of Candida infections in the bloodstream. In consideration of the high incidence of fungal 
infections in these patients, their strong impact on mortality rate, and of the difficulties in 
  Candida diagnosis, some experts suggest the use of antifungal prophylaxis in critically ill surgical 
patients. A clinical benefit from this strategy has been demonstrated, but the economic impact 
of the use of antifungal prophylaxis in surgical patients has not been systematically evaluated, 
and its cost–benefit ratio has not been defined. Whereas the costs associated with treating fun-
gal infections are very high, the cost of antifungal drugs varies from affordable (ie, the older 
azoles) to expensive (ie, echinocandins, polyenes, and the newer azoles). Adverse drug-related 
effects and the possibly increased incidence of fluconazole resistance and of isolates other than 
Candida albicans must also be taken into account. From the published studies of antifungal 
prophylaxis in surgical patients, a likely economic benefit of this strategy could be inferred, but 
its usefulness and cost–benefits should be evaluated in light of local data, because the available 
evidence does not permit general recommendations.
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Introduction
Fungi are a frequent cause of nosocomial infections, with an incidence that has sig-
nificantly increased in recent years.1 It has been reported that Candida is responsible 
for 9% of all nosocomial bloodstream infections in the US2 and that it is the most 
common cause of invasive mycoses.3 Aspergillus species and other emerging fungi, 
such as Fusarium and Rhizopus species, are less frequently isolated, but may cause 
infections in immunocompromised surgical patients. Regarding Candida infections, 
C. albicans accounts for most nosocomial infections, although in some units up to 
50% of Candida infections are due to species other than C. albicans.4,5
In the past, fungi were considered to be etiologic agents of infections essentially 
occurring in neutropenic patients, such as transplant recipients or those with cancer. 
More recently, a role for fungi has been recognized also in infections affecting critically 
ill patients, especially those who require intensive care unit (ICU) admission. Among 
ICU patients, surgical ones have a higher risk of Candida bloodstream infections.6 It 
has been reported that about two-thirds of all episodes of candidemia occur in ICUs 
and in surgical wards,1 and that Candida is the third most common isolate from blood 
in these wards.2 According to data from the National Epidemiology of Mycosis Survey, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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the overall rate of Candida bloodstream infections was 0.98 
per 1000 surgical ICU patient-days and 1.42 per 1000 surgical 
ICU patient-days when a central venous catheter is in place.7 
The higher incidence of fungal infections among surgical 
patients is due to the severity of their underlying diseases, 
impaired gastrointestinal mucosal integrity,   frequency of 
treatment with broad-spectrum antibiotics, and parenteral 
nutrition.3,4
The crude mortality rate for Candida bloodstream infec-
tion ranges from 40% to 60%,8–10 and the mortality rate attrib-
utable to candidemia has been estimated at 25%–38%.11,12 
However, the impact of Candida infections on mortality is 
still controversial. In a matched case-control study carefully 
adjusted for age, severity of illness, and underlying disease, 
it was demonstrated that candidemia did not significantly 
affect mortality in the ICU.13 In contrast, the results of a 
systematic review of studies examining the mortality rate 
related to candidemia suggest that most of the mortality is 
attributable to the infection itself.14
Surgical patients who develop Candida bloodstream 
infections have a mortality rate significantly higher than 
patients in surgical ICUs without this infection.7 Moreover, 
invasive candidiasis is associated with prolonged hospital 
stays.8–10 In a large cohort of ICU patients, it was calculated 
that nosocomial Candida infections were associated with an 
increase of 17 days and 8 days in length of hospital stay and 
ICU stay, respectively.15
A major problem affecting the management of fungal 
infection is the difficulty in making an early diagnosis, given 
the poor sensitivity of diagnostic tests. On the other hand, 
several efficacious antifungal agents are now available with 
a good safety profile.
The high incidence of fungal infections in surgical 
patients, impact on mortality rate, and abovementioned 
diagnostic difficulties have led some experts to sug-
gest the use of antifungal prophylaxis in these patients. 
  However, there is a lack of clear evidence of benefit from 
this   strategy on the incidence of fungal infections and on 
mortality rates.
Although fungal infections, due to their high associated 
morbidity and mortality, have a strong impact on hospital 
costs and on health economic balances, the cost–benefit ratio 
of fungal prophylaxis strategy is not well defined. This review 
summarizes the available evidence for the economic impact 
of antifungal prophylaxis among surgical patients, and briefly 
reports the relevant efficacy data in light of the potential 
cost–benefit ratio.
Which surgical patients are at 
greater risk for fungal infection?
In spite of the identification of several risk factors associated 
with fungal infection among surgical patients, it is not pos-
sible to define a particular group of high-risk patients.
The probability of infection differs according to the type 
of surgical procedure. Patients who undergo abdominal sur-
gery are at highest risk. Patients who undergo neurosurgical 
or ear, nose, and throat procedures are at the lowest risk, 
followed by orthopedic and gynecologic patients.7
A multicenter study including 4276 surgical patients 
identified previous surgery, acute renal failure, and receipt 
of parenteral nutrition as factors independently associated 
with increased risk of Candida bloodstream infections.7 
Other risk factors for fungal infections in surgical patients 
are the severity of the underlying condition,16 duration of 
stay in the ICU, receipt of antibacterial agents, and use of a 
central venous catheter.
Colonization with Candida is another important risk fac-
tor for subsequent invasive infection. The role of Candida 
colonization on the development of subsequent infection has 
been specifically investigated in surgical patients, revealing 
that the intensity and duration of colonization are determin-
ing factors.17 Several risk-predictive models for invasive 
candidiasis among critically ill patients have been published. 
However, they showed suboptimal performance and were not 
validated in independent ICU cohorts.18
Is antifungal prophylaxis efficacious 
in preventing infections in surgical 
patients?
The effectiveness of antifungal prophylaxis is still debated in 
several patient categories. A number of studies on this topic 
have been published, and five meta-analyses have been done 
to reassess the effectiveness and safety of this strategy in 
surgical patients. The characteristics of the patients included 
and the prophylactic strategies analyzed differed between the 
published meta-analyses, but there was some overlap of the 
studies included. Here we report the main findings regarding 
the efficacy of antifungal prophylaxis in surgical patients.
A meta-analysis by Vardakas et al included six   randomized, 
placebo-controlled trials containing 43–292 patients assessing 
the role of azoles in antifungal prophylaxis among high-risk 
surgical ICU patients.19 High-risk patients were defined as 
those having three or more risk factors associated with fungal 
infection, and patients undergoing transplantation were also Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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included if they were expected to stay in the ICU for more 
than five days following surgery. Antifungal agents used in 
the studies were fluconazole 100–400 mg with or without 
a loading dose and administered orally or intravenously, 
  itraconazole 5 mg/kg orally, and ketoconazole 200 mg orally, 
and with a variable duration of prophylaxis. A pooled analysis 
showed that patients receiving azole prophylaxis developed 
significantly fewer fungal infections, including candidemia, 
invasive fungal infections outside the bloodstream, and non-
invasive fungal infections compared with placebo recipients. 
Mortality was significantly lower neither in patients under-
going antifungal prophylaxis, nor in the subgroup analysis 
conducted including only surgical patients.19
The meta-analysis by Cruciani et al included nine ran-
domized controlled trials with 43–292 patients comparing 
systemic antifungal agents with controls in nonneutropenic 
adult ICU surgical or trauma patients.20 Antifungal agents 
used in the included studies were fluconazole 100–400 mg 
with or without a loading dose, administered orally or intra-
venously and ketoconazole 200 mg administered orally or 
parenterally compared with placebo or with no treatment/
nystatin/clotrimazole. The length of prophylaxis differed 
among the studies. This pooled analysis also showed that 
the probability of Candida infection in patients who received 
antifungal prophylaxis was significantly lower. Interestingly, 
the metaregression showed that neither the azole prescribed 
nor the Acute Physiology and Chronic Health Evaluation 
(APACHE) II score influenced treatment effects. Moreover, 
this meta-analysis demonstrated a 79% reduction in mortality 
attributable to Candida infection in azole-treated patients. 
Overall mortality was also significantly reduced.20
The meta-analysis by Playford et al included 12 random-
ized controlled trials including 38–292 patients and evalu-
ated the effect of any antifungal regimen in nonneutropenic 
critically ill patients.21 This meta-analysis also included 
nonsurgical patients, but the majority of those included were 
postsurgical ICU patients. Eight trials compared fluconazole 
100–400 mg with or without a loading dose administered 
orally or intravenously, with no antifungal therapy, and four 
compared ketoconazole 200–400 mg administered orally 
with no antifungal treatment or a nonadsorbable agent. 
The duration of prophylaxis differed among the studies. 
The fluconazole and ketoconazole trials analyzed sepa-
rately did not show a significant reduction of mortality risk. 
Fluconazole significantly reduced the incidence of proven 
invasive fungal infections. When the trials were analyzed 
together, fluconazole and ketoconazole were found to reduce 
total mortality and invasive infections. Subgroup analysis of 
postsurgical patients demonstrated a significant reduction of 
proven invasive infections and mortality in the fluconazole 
and ketoconazole prophylaxis groups.21
The meta-analysis by Shorr et al included four random-
ized trials with 43–260 patients comparing fluconazole with 
placebo in critically ill surgical patients. There was hetero-
geneity among the trials with respect to fluconazole dosing 
(100–400 mg/day, with or without a loading dose), route of 
administration (orally or intravenously or both), and dura-
tion of the prophylactic regimen. The authors of this meta-
analysis reported that prophylaxis significantly reduced the 
incidence of fungal infections but was not associated with a 
lower mortality rate. The incidence of candidemia was not 
significantly reduced in the fluconazole group.22
The meta-analysis by Ho et al included seven random-
ized controlled trials of fluconazole prophylaxis involving 
immunocompetent critically ill or high-risk surgical patients, 
excluding studies that included liver transplanted or neutro-
penic cancer patients.23 The numbers of patients included 
in the trials ranged from 43 to 260, doses of fluconazole 
ranged from 100 to 800 mg/day, and the duration of the 
prophylactic regimen varied between the studies. Candidemia 
was significantly less frequent in the fluconazole group, but 
hospital mortality and total length of hospital stay did not 
differ between the two groups.23
In conclusion, these meta-analyses showed a clinical ben-
efit of antifungal prophylaxis in patients at different degrees 
of risk. Only two pooled analyses showed significantly lower 
mortality rates. However, due to the inadequate sample 
size of the trials and the heterogeneity in type and dosage 
of antifungal agent, duration of prophylaxis, and patient 
  characteristics, it is not possible to identify a clear indication 
for a prophylactic antifungal strategy from these studies.
Costs of antifungal prophylaxis
When considering the economic balance of antifungal 
  prophylaxis, it is necessary to take into account several cost 
components. First, the economic consequences of fungal 
infection must be considered. A multicenter Spanish study 
assessed the economic impact of Candida colonization and 
Candida infection in critically ill patients admitted to an 
ICU. Candida colonization resulted in an additional €8000 
and Candida infection in almost €16,000 in direct costs, 
respectively.24
A prospective cohort study of Candida infections con-
ducted in the medical and surgical ICUs of a large US hospital Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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reported an unadjusted median cost of $41,832 for patients 
with Candida infections and of $19,252 for those without 
Candida infections.15 A cost per ICU patient-day of $230 
was also calculated.15
A multiple linear regression model was used to determine 
the cost of an ICU admission attributable to Candida infec-
tion and to verify if clinical factors other than fungal infection 
have an impact on the cost of an ICU admission. Candida 
infections were associated with a median increase in the cost 
of $21,590 per patient and, in particular, with significantly 
increased costs in the service categories of room and board 
($16,549), pharmacy ($5501), laboratory ($8216), supplies 
($3289), and physical and occupational therapy ($2677). 
The variable that most strongly affected cost was the length 
of stay in the ICU.15 The results of a random effects model 
revealed that the daily ICU cost did not change after patients 
became infected with Candida, confirming that the increase 
in ICU cost is probably due to the increased length of stay 
rather than increased daily ICU cost.15
Another US study specifically assessed the estimated 
costs of care associated with candidemia over an entire 
  hospital stay.10 The increase in cost of care during hospi-
talization was $44,536 and $34,123 in patients receiving 
private insurance and Medicare, respectively.10 The total cost 
included expenditure for diagnostic procedures, antifungal 
therapy, hospital stay, adverse drug reactions, and switch 
therapy because of adverse drug reactions.10 The largest 
component of total cost was due to protracted hospital stays. 
The results of a regression analysis performed to control for 
factors that may influence length of hospitalization showed 
that candidemia had the most impact.10
The acquisition cost of antifungal agent is also an impor-
tant component of prophylaxis expenditure. Table 1 sum-
marizes the costs of commercial available antifungal agents. 
Economic cost widely varies depending on the drug, the 
dosage used, route of administration, and total duration of 
prophylactic treatment. For example, published trials have 
reported fluconazole dosages of 100–400 mg/day preceded 
by a loading dose of 800 mg and administration by the 
parenteral or enteral route, with different costs. Costs of 
antifungal agents vary between countries and hospitals, and 
may differ if the drug is administered during   hospitalization, 
at a long-term care facility, or in an outpatient setting. Flu-
conazole is the drug most frequently used in prophylactic 
regimens. It is inexpensive and its pricing is expected to be 
reduced following the expiration of its patented life. The 
guidelines from the Infectious Diseases Society of America 
recommend fluconazole 6 mg/kg/day as an antifungal agent 
for prophylaxis in high-risk ICU patients.25
The antifungal profile and pharmacokinetic parameters of 
the echinocandins (caspofungin, micafungin, anidulafungin) 
could make them good choices for antifungal prophylaxis. 
However, these agents are expensive and need to be admin-
istered intravenously. Similarly, the high cost and need for 
parenteral infusion limits the use of lipid formulations of 
amphotericin B.
The economic cost of the side effects associated with 
antifungal agents must also be considered. The costs 
Table 1 Costs of antifungal agents
Antifungal agent (usual dosage) Product cost (US$) Estimated daily cost* 
Amphotericin B 0.5–1.0 mg/kg/iv/day $12/50 mg vial $12–24
L-Amphotericin B 1–5 mg/kg/iv/day $188/50 mg vial  $263–1316
Fluconazole 400 mg/day orally or iv $8/200 mg tablet 
$88/400 mg iv
$16 for oral administration 
$88 for iv administration
itraconazole 200 mg/day orally or 200 mg/day iv $10/100 mg capsules 
$158/200 mg vial
$20 for oral administration 
$158 for iv administration
Ketoconazole 400 mg/day orally $5/200 mg tab $10
Posaconazole 600–800 mg/day orally $576/105 mL susp (40 mg/mL) $82–110
Voriconazole 6 mg/kg/IV q12h first day, then  
3 mg/kg/iv q12h or 400 mg orally q12h on day 1  
followed by 200 mg orally q12h
$121/200 mg vial 
$39/200 mg tab
$508 first day then $255 for  
iv administration 
$156 first day then $78 for oral 
administration
Anidulafungin 100–200 mg/IV first day followed  
by 50–100 mg/iv/day
$112/50 mg vial $224–448 first day then $112–224
Caspofungin 70 mg/IV first day followed  
by 50 mg/day iv
$395/70 mg vial 
$395/50 mg vial
$395
Micafungin 50–150 mg/day iv $112/50 mg vial $112–336
Notes: *For a 70 kg patient. All cost data were extracted from the 2007 Drug Topics Redbook, Thomson Healthcare, inc.
Abbreviations: L, liposomal; iv, intravenous; q, quondam; h, hours; cps, capsule; tab, tablet; susp, suspension.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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associated with drug-related adverse events depend on 
their incidence and severity, and are calculated taking into 
account the costs of several components, including loss of 
life-years, loss of quality life-years, long-term morbidity of 
selected adverse events, and an extended hospital stay due 
to an adverse event.
Fluconazole is generally well tolerated, with a very low 
incidence of serious adverse effects, and the new azoles and 
echinocandins have low toxicity rates. On the other hand, 
administration of amphotericin B or liposomal amphotericin 
is frequently associated with nephrotoxicity.
Some of the aforementioned meta-analyses explored 
the incidence of toxicity due to antifungal prophylaxis. 
  Comparing azoles with placebo, there was no significant dif-
ference in the incidence of side effects.19 The pooled analysis 
that included trials comparing fluconazole or ketoconazole 
with no antifungal therapy or with nonadsorbable agents 
showed no difference in the occurrence of severe adverse 
events. Shorr et al, reviewing the safety of fluconazole pro-
phylaxis, reported that rates of laboratory abnormalities were 
similar across all the studies that presented safety data, and 
did not differ between the intervention and placebo arms. 
No deaths were attributed to fluconazole administration, and 
intervention was stopped in only five patients (two on flucon-
azole and three on placebo) because of toxicity concerns.22
Another important economic consequence is the poten-
tial impact of prophylaxis on the emergence of antifungal 
resistance and on the prevalence of different fungal species. 
This effect is linked to the “ecological cost” of antifungal 
prophylaxis. Ecological costs represent the costs paid by 
future patients given inappropriate treatment due to the 
higher resistance to frequently used antifungal agents and 
by individual patient costs, ie, the costs of development of 
resistance in the individual patient, assuming that antifungal 
use will change the flora in the individual.
Above all, azole use has been linked to an increased 
incidence of fluconazole-resistant Candida isolates and 
to a shift towards isolation of Candida species other than 
C. albicans. Exposure to fluconazole is an already known 
risk factor associated with fluconazole resistance,26 and sev-
eral investigators have reported an increased frequency of 
  isolation of C. glabrata subsequent to azole use.27–29 These 
phenomena would have a strong impact on mortality from 
Candida infections. It has been shown that Candida species 
other than C. albicans have a worse prognosis.30–32   Similarly, 
in critically ill patients, infection with Candida strains 
resistant to fluconazole doubles the risk of death.33 As a 
consequence, a higher mortality rate would be   responsible 
for an increase in costs. Moreover, in a setting with a higher 
prevalence of fluconazole-resistant Candida and of isolates 
other than C. albicans, the antifungal options would include 
the newer azoles and echinocandins, with a further significant 
increase in costs.
Resistance to echinocandins and the newer azoles 
would also increase as a consequence of greater use, so the 
cost–benefit of antifungal prophylaxis would be even more 
unfavorable. The role of antifungal prophylaxis in the emer-
gence of resistant Candida and strains other than C. albicans 
is still controversial. An observational study in a surgical 
ICU where fluconazole prophylaxis had been utilized for 
three years, revealed that, when invasive candidiasis occurs, 
the causative agent is likely to have reduced susceptibility to 
fluconazole, whether or not it was ICU-acquired.34 However, 
three meta-analyses of azole prophylaxis reported neither 
development of resistance among the fungal isolates nor a 
shift from C. albicans toward other Candida species.19,20,23
The economic impact of the use of antifungal prophylaxis 
in surgical patients has not been systematically evaluated, but 
some authors have tried to extrapolate economic data from 
their investigations on antifungal prophylaxis.
In a double-blind, placebo-controlled trial evaluating the 
prophylactic use of enteral fluconazole to prevent Candida 
infections in 260 critically ill surgical patients, it was calcu-
lated that the number needed to treat to prevent one fungal 
infection was 9.5.35 The authors chose the enteral rather than 
the intravenous route for fluconazole because it costs less 
and has good bioavailability. The cost for a 400 mg dose 
was $90, whereas the calculated cost of Candida infections 
was $230 per ICU patient-day.15 It was concluded that, given 
the low cost of enteral fluconazole and the low number of 
patients needed to treat to prevent fungal infections, the use 
of antifungal prophylaxis in this population is likely to be 
cost-effective.
Similarly Ho et al, with a baseline risk of candidemia 
that in the placebo arm of their meta-analysis was 4.5%, 
calculated that 25 patients would need to be treated to prevent 
one episode of candidemia. Assuming a cost of $490 for a 
2-week prophylactic course of fluconazole per patient, the 
cost to prevent one episode of candidemia would be $12,250, 
which is markedly less expensive than the calculated cost of 
each episode of candidemia.23
A study that investigated a risk-based fluconazole pro-
phylaxis program included 36 patients admitted to a   medical 
ICU.36 It was reported that the total cost of fluconazole 
prophylaxis was $6000, which is much less expensive than 
the $567,000 of excess health care costs associated with Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
18
Cataldo and Petrosillo
nine episodes of Candida bloodstream infection that occurred 
in the same unit before the start of the prophylaxis program.36 
However, these data do not refer to surgical patients, and 
the study was conducted in a small ICU and consequently 
analyzed very few episodes of candidiasis.
Some authors have suggested that a more efficacious and 
economically feasible strategy could be to utilize colonization 
screening to guide the choice of patients who would ben-
efit from antifungal prophylaxis. Candida colonization has 
been recognized as an important risk factor for subsequent 
  infection, and it has been reported that, in the absence of fun-
gal colonization, infection is unlikely.16 However, its positive 
predictive value of infection ranges between 12% and 18%. 
Moreover, the variability in design of the published studies 
and in the reporting of the extent and duration of colonization 
does not allow us to give an exact indication on how to use 
colonization data for this purpose. Interestingly, the corrected 
colonization index, ie, ratio of highly positive samples to the 
total number of samples cultured, developed by Pittet et al,17 
was utilized in a before-after study to guide the decision about 
which patients should receive pre-emptive treatment with 
fluconazole.26 The incidence of proven surgical ICU-acquired 
candidiasis significantly decreased while the incidence of 
imported candidiasis did not change.26 A corrected coloniza-
tion index cutoff of 0.4 was defined as a probable indication 
of unnecessary prophylaxis. This strategy would probably be 
less expensive than if prophylaxis was administered to all 
patients, but the cost of mycological screening performed on 
all admitted patients is not negligible. No specific economic 
data are available for this strategy.
Discussion
The costs of fungal infections are very high, and surgical 
patients seem to be at greater risk for developing serious 
and invasive Candida infections, with a high mortality rate. 
The azoles are affordable, but the incidence of fluconazole 
resistance with isolates other than C. albicans needs to be 
investigated further because the available evidence does 
not exclude a strong impact on these phenomena. Similarly, 
further studies with adequate sample sizes are needed to 
define better the adverse effect profile of azole prophylaxis, 
particularly for hepatotoxicity.
Obviously, the economic balance of a prophylaxis 
strategy does not result from a simple opposition of the 
cost associated with Candida infections against the cost for 
antifungal agents and the related side effects.
The economic advantage of antifungal prophylaxis is 
linked to the incidence of infection and to the impact of 
  prophylaxis on mortality. The fungal infection rates reported 
by the published studies are variable and consequently the 
data on efficacy and cost are not generalizable. Also, the 
incidence of invasive infections in surgical ICUs varies 
widely between hospitals, and all the trials have the limita-
tions of being heterogeneous and including small patient 
populations.
If we can identify patients at very high risk for infection 
and administer a prophylactic regimen only to a selected 
  population, the economic balance would probably be   favorable. 
Unfortunately, there is not a defined group of patients at great-
est risk as yet, and the strategy of colonization screening has 
many gaps and needs further investigation.
Some experts have suggested that prophylaxis would be 
advantageous when the rate of candidemia is at least 10%.37 
However, Ho et al reported a likely cost–benefit of antifun-
gal prophylaxis pooling studies with a baseline candidemia 
risk of 4.5%.
Recently published guidelines for the management of 
candidiasis recommend the use of antifungal prophylaxis in 
patients at high risk (.10%) of invasive candidiasis hospital-
ized in ICUs with very high rates compared with the “normal 
rates” of 1%–2%.25
Another essential determinant of the economic balance 
is the actual impact of antifungal prophylaxis on the mor-
tality rate. Not all published trials found lower mortality 
in the treated groups, and the pooled analyses performed 
by different investigators yielded conflicting results. The 
meta-analysis by Cruciani et al reported a reduction in 
mortality attributable to Candida infection and in overall 
mortality in the azole-treated group.20 In the meta-analysis 
by Playford et al, the subgroup analysis of postsurgical 
patients demonstrated a significant mortality reduction in 
the fluconazole/ketoconazole prophylaxis groups.21 The other 
meta-analyses failed to show a benefit on mortality rate.19,22,23 
The inability to detect a survival advantage with antifungal 
prophylaxis might be due to small sample sizes and to the 
selection of populations at insufficiently high risk to show 
a benefit. Future studies are needed with adequate sample 
sizes to define better the highest risk surgical population, 
and to assess the impact of prophylaxis on the incidence of 
infection and mortality. 
A likely economic benefit of this strategy does emerge 
from the published studies on antifungal prophylaxis in sur-
gical patients, but a specific cost-benefit analysis is lacking 
and is urgently needed.
The usefulness and the cost–benefit of antifungal prophy-
laxis in surgical patients should be evaluated in each surgical Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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unit in light of local data concerning the incidence of invasive 
Candida infections and the clinical and   epidemiological char-
acteristics of the patient population treated, because the avail-
able evidence does not permit a universal recommendation.
It is important to underscore that, beyond prophylaxis 
with antifungal agents, standard measures to prevent noso-
comial infections should always be applied both for their 
efficacy and for their low cost. Because transmission of 
Candida could occur via the hands of health care workers, 
especially during the care of catheters, all hospitals need to 
improve their adherence to hand hygiene. Also, extremely 
important is adherence to current recommendations for 
placement and care of central venous catheters. Finally, the 
correct use of antibiotics is another important component 
of candidemia prevention that would lead to a decrease in 
economic and ecological costs.
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